SavedAdd your journal

Journals / ENT Updates / 2020 / Cilt: 10 - Sayı: 3

The effects of Sulindac on cell viability, cell cycle and angiogenesis in pharyngeal cancer cells

Fatih AĞDAŞ
Aylin ERYILMAZ
Esra Gökmen YILMAZ
Kemal ERGİN
Pages
373–380
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sulindac was foundto slightly increase vascular endothelial growth factorreceptor 2 (VEGF-R2) and decrease ADAMTS1 levels inpharyngeal cancer cells.Conclusion: Sulindac showed positive results on cell proliferation in the treatment of pharyngeal cancer cells.However, it could cause a slight increase in angiogenesis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The present study aimed to investigate the effects of Sulindac on cell viability, cell cycle and angiogenesis in pharyngeal cancer cell lines (FaDu).Methods: FaDu cells were incubated in a medium in a5% CO2 incubator at 37°C, after which they were proliferated and passaged.
📊
Key Findings & Data:IC50 concentration was used todetermine the Sulindac dose.
💡
Conclusion & Impact:Sulindac was foundto slightly increase vascular endothelial growth factorreceptor 2 (VEGF-R2) and decrease ADAMTS1 levels inpharyngeal cancer cells.Conclusion: Sulindac showed positive results on cell proliferation in the treatment of pharyngeal cancer cells.However, it could cause a slight increase in angiogenesis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: The present study aimed to investigate the effects of Sulindac on cell viability, cell cycle and angiogenesis in pharyngeal cancer cell lines (FaDu).Methods: FaDu cells were incubated in a medium in a5% CO2 incubator at 37°C, after which they were proliferated and passaged. IC50 concentration was used todetermine the Sulindac dose. Cells were analyzed for cellviability, cell count and cell cycle after Sulindac administration. Immunohistochemistry (vascular endothelialgrowth factor receptor 2) and western blot (A disintegrinand metalloproteinase with thrombospondin-like motifs1-ADAMTS1) analyses were used for angiogenesis assessment.Results: Cell viability decreased in pharyngeal cancer cellsafter Sulindac administration. In addition, FaDU cellswere arrested in the G2/M phase. Sulindac was foundto slightly increase vascular endothelial growth factorreceptor 2 (VEGF-R2) and decrease ADAMTS1 levels inpharyngeal cancer cells.Conclusion: Sulindac showed positive results on cell proliferation in the treatment of pharyngeal cancer cells.However, it could cause a slight increase in angiogenesis.

🔖

Cite This Article

AĞDAŞ, F., ERYILMAZ, A., YILMAZ, E. G., ERGİN, K. (2020). The effects of Sulindac on cell viability, cell cycle and angiogenesis in pharyngeal cancer cells. ENT Updates, Cilt: 10 - Sayı: 3, 373–380. https://ajindex.com/articles/348199

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Scheper MA, Nikitakis NG, Chaisuparat R, Montaner S, Sauk JJ. Sulindac induces apoptosis and inhibits tumor growth in vivo in head and neck squamous cell carcinoma. Neoplasia 2007;9:192-9
  2. Forastiere AA, Trotti A, Pfister DG, Grandis JR. Head and neck cancer: recent advances and new standards of care. J Clin Oncol 2006;24:2603-5
  3. Carla C, Daris F, Cecilia B, Francesca B, Francesca C, Paolo F. Angiogenesis in head and neck cancer: a review of the literature. J Oncol 2012;2012:358472
  4. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116- 27
  5. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006;55:115-22
  6. Mohan S, Epstein JB. Carcinogenesis and cyclooxygenase: the potential role of COX-2 inhibition in upper aerodigestive tract cancer. Oral Oncol 2003;39:537-46
  7. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002;24:792-9
  8. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96- 102
  9. Fu SL, Wu YL, Zhang YP, Qiao MM, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004;10:1971-4
  10. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997;57:267-71
  11. Castonguay A, Rioux N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis 1997;18:491- 6
  12. Oida Y, Gopalan B, Miyahara R, et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther 2005;4:291-304
  13. Dvory-Sobol H, Kazanov D, Liberman E, et al. MF tricyclic and sulindac retard tumor formation in an animal model. Int J Cancer 2006;118:11-6
  14. Sun BC, Zhao XL, Zhang SW, Liu YX, Wang L, Wang X. Sulindac induces apoptosis and protects against colon carcinoma in mice. World J Gastroenterol 2005;11:2822-6
  15. Teicher BA, Korbut TT, Menon K, Holden SA, Ara G. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies. Cancer Chemother Pharmacol 1994;33:515-22
  16. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against hu